Avalo Therapeutics earnings release, August 6, 2026

Avalo Therapeutics, Inc. (AVTX) · Form 8-K, Item 2.02 · Filed · SEC filing

Avalo Therapeutics Reports Second Quarter 2026 Financial Results and Recent Business Updates

• Plans to initiate a registrational Phase 3 program evaluating abdakibart in hidradenitis suppurativa (HS) in the first half of 2027

• Expanded pipeline with AVTX-010, a long-acting next-generation anti-IL-1β antibody, with IND submission planned for the first half of 2027

• Appointed Ron Philip to the Board of Directors

• Cash, cash equivalents and investments of $472.2 million as of June 30, 2026, expected to provide runway into 2029

WAYNE, PA., August 6, 2026 — Avalo Therapeutics, Inc. (Nasdaq: AVTX), a clinical stage biotechnology company dedicated to developing therapeutics targeting the IL-1β pathway for immune-mediated inflammatory diseases, today announced business updates and financial results for the second quarter of 2026.

“In the second quarter, we achieved the key objectives that positioned Avalo for its next phase of growth,” said Garry Neil, MD, Chief Executive Officer of Avalo. “We delivered positive topline Phase 2 LOTUS results for abdakibart in HS, secured the capital to take it into a registrational Phase 3 program in HS, and expanded our pipeline with AVTX-010, a long-acting next-generation anti-IL-1β antibody. Our focus now is execution – starting with advancing abdakibart, which we believe has the potential to offer best in disease efficacy, safety and dosing convenience, toward Phase 3 initiation in HS as well as building a broader IL-1β franchise.”

Recent Corporate Highlights and Upcoming Anticipated Milestones

• Avalo plans to initiate a registrational Phase 3 program evaluating abdakibart in HS in the first half of 2027.

• Announced the advancement of AVTX-010, a long-acting next-generation anti-IL-1β monoclonal antibody with the potential for development in HS as well as other inflammatory disorders. The Company expects to submit an Investigational New Drug (IND) application in the first half of 2027.

• Appointed Ron Philip to its Board of Directors. Ron contributes deep strategic and commercial expertise, with a proven track record of bringing novel therapies to market.

• Added to the Russell 2000® and Russell 3000®

Indexes as part of the FTSE Russell annual reconstitution.

Second Quarter 2026 Financial Update:

• Cash, cash equivalents and investments were $472.2 million as of June 30, 2026. Net cash used in operating activities was $37.7 million for the six months ended June 30, 2026. Avalo’s current cash, cash equivalents, and investments are expected to fund operations into 2029.

• Research and development expenses were $23.4 million for the second quarter of 2026, an increase of $9.3 million from the second quarter of 2025, driven by the recognition of a $10.0 million development milestone for abdakibart, as well as costs related to and supporting the development of abdakibart in HS.

• General and administrative expenses were $8.1 million for the second quarter of 2026, an increase of $2.9 million from the second quarter of 2025, primarily driven by stock-based compensation expense.¹

• Net loss was $36.4 million for the second quarter of 2026, an increase of $15.6 million from the second quarter of 2025. The difference was mainly driven by a $12.2 million increase in operating expenses due to the $9.3 million increase in research and development expenses and $2.9 million increase in general and administrative expenses, as discussed above. Basic and diluted net loss per share was $0.83 and $1.92 for the second quarters of 2026 and 2025, based on 43,602,044 and 10,829,760 weighted average common shares outstanding, respectively.²

Consolidated Balance Sheets

(In thousands, except share and per share data)

The consolidated balance sheets as of June 30, 2026 and December 31, 2025 have been derived from the reviewed and audited financial statements, respectively, but do not include all of the information and footnotes required by accounting principles accepted in the United States for complete financial statements.³

Consolidated Statements of Operations

(In thousands, except per share data)

The unaudited consolidated statements of operations for the three and six months ended June 30, 2026 and 2025 have been derived from the reviewed financial statements, but do not include all of the information and footnotes required by accounting principles generally accepted in the United States for complete financial statements.⁴

About Avalo Therapeutics

Avalo Therapeutics is a clinical stage biotechnology company dedicated to developing therapeutics targeting the IL-1β pathway for immune-mediated inflammatory diseases. Avalo is advancing its lead anti-IL-1β monoclonal antibody (mAb) drug candidate, abdakibart, into a phase 3 registrational program in hidradenitis suppurativa (HS), a chronic inflammatory skin condition that affects an estimated 1-4% of the population globally. Avalo is pursuing additional development opportunities in IL-1β driven indications. Avalo is also developing AVTX-010, a long-acting next-generation anti-IL-1β mAb. For more information about Avalo, please visit www.avalotx.com.

About Abdakibart

Abdakibart is a humanized monoclonal antibody (IgG4) that binds to interleukin-1β (IL-1β) with high affinity and neutralizes its activity. IL-1β is a pro-inflammatory cytokine that plays a central role in the pathogenesis of a wide range of human diseases.

It activates immune cells that generate proinflammatory cytokines, including IL-6, TNF-α, and IL-17. Dysregulated IL-1β signaling is a major driver of inflammation, contributing to the progression of autoimmune disorders. IL-1β inhibition has proven effective in multiple immune-mediated inflammatory diseases.

About AVTX-010

AVTX-010 is an Fc-engineered, long-acting anti-IL-1β monoclonal antibody designed to extend half-life while preserving the pharmacology and specificity of abdakibart.

Financial statements

Income Statement

Three Months Ended — (In thousands, except per share data)

Three Months Ended – June 30, – 2026Three Months Ended – June 30, – 2025Six Months Ended – June 30, – 2026Six Months Ended – June 30, – 2025
Operating expenses:Research and development23,41814,07437,46623,195
Operating expenses:General and administrative8,0995,24214,95310,789
Operating expenses:Total operating expenses31,51719,31652,41933,984
Operating expenses:Loss from operations-31,517-19,316-52,419-33,984
Other (expense) income:Change in fair value of derivative liability-1,010-2,530-530-2,150
Other (expense) income:Change in fair value of contingent consideration-6,574-6,574
Other (expense) income:Interest income, net2,7611,0973,5642,244
Other (expense) income:Total other (expense) income, net-4,823-1,433-3,54094
Other (expense) income:Loss before taxes-36,340-20,749-55,959-33,890
Other (expense) income:Income tax expense18162924
Other (expense) income:Net loss-36,358-20,765-55,988-33,914
Other (expense) income:Net loss per share of common stock, basic and diluted-0.83-1.92-1.75-3.18
Other (expense) income:Weighted average common shares outstanding43,602,04410,829,76031,919,38810,673,200
Comprehensive loss:Net loss-36,358-20,765-55,988-33,914
Other comprehensive loss:Unrealized loss on investments, net-577-34-651-34
Other comprehensive loss:Comprehensive loss-36,935-20,799-56,639-33,948

Balance Sheet

June 30, 2026 — (In thousands, except share and per share data)

June 30, 2026 – (unaudited)December 31, 2025
Current assets:Cash and cash equivalents85,38215,858
Current assets:Short-term investments314,89482,478
Current assets:Prepaid expenses and other current assets7,6076,913
Current assets:Restricted cash, current portion4937
Current assets:Total current assets407,932105,286
Current assets:Long-term investments71,878
Current assets:Property and equipment, net288460
Current assets:Goodwill10,50210,502
Current assets:Restricted cash, net of current portion183210
Current assets:Total assets490,783116,458
Current liabilities:Accounts payable3,347137
Current liabilities:Accrued expenses and other current liabilities17,78312,803
Current liabilities:Total current liabilities21,13012,940
Current liabilities:Royalty obligation2,0002,000
Current liabilities:Deferred tax liability, net463434
Current liabilities:Derivative liability, non-current18,53018,000
Current liabilities:Other long-term liabilities35
Current liabilities:Total liabilities42,12333,409
Stockholders’ equity:Common stock—$0.001 par value; 200,000,000 shares authorized at June 30, 2026 and December 31, 2025; 52,900,692 and 18,512,757 shares issued and outstanding at June 30, 2026 and December 31, 2025, respectively5318
Stockholders’ equity:Additional paid-in capital953,700531,485
Stockholders’ equity:Accumulated other comprehensive (loss) income-58368
Stockholders’ equity:Accumulated deficit-504,510-448,522
Stockholders’ equity:Total stockholders’ equity448,66083,049
Stockholders’ equity:Total liabilities, mezzanine equity and stockholders’ equity490,783116,458
Full release

Forward-Looking Statements... (truncated)rsuant to the Private Securities Litigation Reform Act of 1995 and other federal securities laws. Forward-looking statements are statements that are not historical facts. Such forward-looking statements are subject to significant risks and uncertainties that are subject to change based on various factors (many of which are beyond our control), which could cause actual results to differ from the forward-looking statements. Such statements may include, without limitation, statements with respect to our plans, objectives, projections, expectations and intentions and other statements identified by words such as “projects,” “may,” “might,” “will,” “could,” “would,” “should,” “continue,” “seeks,” “aims,” “predicts,” “believes,” “expects,” “anticipates,” “estimates,” “intends,” “plans,” “potential,” or similar expressions (including their use in the negative), or by discussions of future matters such as: therapeutic potential, clinical benefits and safety profiles of abdakibart (AVTX-009); plans to advance abdakibart into a registrational phase 3 program; plans to advance AVTX-010 into clinical trials; the timing of an IND submission for AVTX-010 in the first half of 2027; our financial condition and expected cash runway into 2029; expectations regarding timing, success and data announcements of ongoing preclinical studies and clinical trials; drug development costs, reliance on investigators and enrollment of patients in clinical trials; and our plans to develop and commercialize our current and any future product candidates and the implementation of our business model and strategic plans for our business.

Any forward-looking statements are based on management’s current expectations and beliefs and are subject to a number of risks, uncertainties and important factors that may cause actual events or results to differ materially from those expressed or implied by any forward-looking statements including, without limitation, risks associated with: the timing and anticipated results of our current and future preclinical studies and clinical trials, supply chain, strategy and future operations; the delay of any current and future preclinical studies or clinical trials or the development of our product candidates; the risk that the results of prior preclinical studies and clinical trials may not be predictive of future results in connection with current or future preclinical studies and clinical trials, including those for abdakibart and AVTX-010; the timing and outcome of any interactions with regulatory authorities; obtaining, maintaining and protecting our intellectual property; the availability of funding sufficient for our operating expenses and capital expenditure requirements, reliance on key personnel; regulatory risks; general economic and market risks and uncertainties, including those caused by the war in Ukraine and the Middle East; and those other risks detailed in our filings with the Securities and Exchange Commission, available at www.sec.gov. We may not actually achieve the plans, intentions or expectations disclosed in our forward-looking statements, and you should not place undue reliance on our forward-looking statements. In addition, any forward-looking statements represent our view only as of today and should not be⁵ relied upon as representing its views as of any subsequent date. You should not rely upon forward-looking statements as predictions of future events and actual results or events could differ materially from the plans, intentions and expectations disclosed herein. Except as required by applicable law, we expressly disclaim any obligations or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in our expectations with respect thereto or any change in events, conditions or circumstances on which any statement is based.

For media and investor inquiries

Christopher Sullivan, CFO

Avalo Therapeutics, Inc. ir@avalotx.com

410-803-6793 or

Meru Advisors

Lauren Glaser lglaser@meruadvisors.com⁶

From SEC EDGAR. Analysis by Pear Digitals from the filing alone. Not investment advice. · Avalo Therapeutics earnings · Latest earnings · Markdown

Screener

Plans

Premium and Pro coming soon.

Log in

New here?

Join the waitlist

Pear FMV opens to everyone soon. We'll email you when it does.